Choosing the appropriate GLP-1 receptor agonist depends on your individual health profile, treatment goals, and lifestyle preferences
Cochrane-standard systematic reviews have examined the randomized controlled trial data across multiple GLP-1 medications, and the weight of the published evidence supports the conclusion that in properly selected patients, GLP-1 receptor agonists produce clinically meaningful weight loss that exceeds what diet and exercise alone typically achieve without pharmacological support
Eli Lillys daily anti-obesity pill orforglipron appears to be as good at spurring weight loss and lowering blood sugar in diabetes patients as popular injectable GLP-1 drugs like Ozempic, according to new data from a Phase 3 trial
Canadian Access and Coverage Considerations Canadian patients face unique considerations when evaluating these medications
at 1111B S Governors Ave, STE 25428, Dover, DE 19904, and the address is published in the terms of service and easy to verify through state corporate records
If taste changes significantly impair nutrition or quality of life despite management strategies, your healthcare provider may consider dose reduction, temporary treatment interruption, or switching to an alternative medication
